St Laurent Jessica D, Lin Lawrence H, Owen David M, Maestá Izildinha, Castaneda Arnold, Hasselblatt Kathleen T, Goldstein Donald P, Horowitz Neil S, Berkowitz Ross S, Elias Kevin M
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Brigham and Women's Hospital, 75 Francis St., Boston, MA, 02115, USA.
New England Trophoblastic Disease Center, Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Biology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, 75 Francis St, Boston, MA, 02115, USA.
Reprod Sci. 2021 Nov;28(11):3200-3211. doi: 10.1007/s43032-021-00634-y. Epub 2021 Jun 15.
To investigate if differences in imprinting at tropho-microRNA (miRNA) genomic clusters can distinguish between pre-gestational trophoblastic neoplasia cases (pre-GTN) and benign complete hydatidiform mole (CHM) cases at the time of initial uterine evacuation. miRNA sequencing was performed on frozen tissue from 39 CHM cases including 9 GTN cases. DIO3, DLK1, RTL1, and MEG 3 mRNA levels were assessed by qRT-PCR. Protein abundance was assessed by Western blot for DIO3, DLK1, and RTL1. qRT-PCR and Western blot were performed for selenoproteins and markers of oxidative stress. Immunohistochemistry (IHC) was performed for DIO3 on an independent validation set of clinical samples (n = 42) and compared to normal placenta controls across gestational ages. Relative expression of the 14q32 miRNA cluster was lower in pre-GTN cases. There were no differences in protein abundance of DLK1 or RTL1. Notably, there was lower protein expression of DIO3 in pre-GTN cases (5-fold, p < 0.03). There were no differences in mRNA levels of DIO3, DLK1, RTL1 or MEG 3. mRNA levels were higher in all CHM cases compared to normal placenta. IHC showed syncytiotrophoblast-specific DIO3 immunostaining in benign CHM cases and normal placenta, while pre-GTN cases of CHM lacked DIO3 expression. We describe two new biomarkers of pre-GTN CHM cases: decreased 14q32 miRNA expression and loss of DIO3 expression by IHC. Differences in imprinting between benign CHM and pre-GTN cases may provide insight into the fundamental development of CHM.
为研究滋养层微小RNA(miRNA)基因组簇印记差异能否在初次子宫排空时区分妊娠前滋养细胞肿瘤病例(pre-GTN)和良性完全性葡萄胎(CHM)病例。对39例CHM病例(包括9例GTN病例)的冷冻组织进行miRNA测序。通过qRT-PCR评估DIO3、DLK1、RTL1和MEG 3 mRNA水平。通过蛋白质印迹法评估DIO3、DLK1和RTL1的蛋白质丰度。对硒蛋白和氧化应激标志物进行qRT-PCR和蛋白质印迹分析。在一组独立的临床样本(n = 42)上对DIO3进行免疫组织化学(IHC)检测,并与不同孕周的正常胎盘对照进行比较。pre-GTN病例中14q32 miRNA簇的相对表达较低。DLK1或RTL1的蛋白质丰度没有差异。值得注意的是,pre-GTN病例中DIO3的蛋白质表达较低(5倍,p < 0.03)。DIO3、DLK1、RTL1或MEG 3的mRNA水平没有差异。所有CHM病例的mRNA水平均高于正常胎盘。免疫组织化学显示良性CHM病例和正常胎盘中合体滋养层特异性DIO3免疫染色,而CHM的pre-GTN病例缺乏DIO3表达。我们描述了pre-GTN CHM病例的两个新生物标志物:14q32 miRNA表达降低和免疫组织化学检测显示DIO3表达缺失。良性CHM和pre-GTN病例之间的印记差异可能有助于深入了解CHM的基本发育过程。